NEW YORK, NY – Today, the Crohn’s & Colitis Foundation released its new five-year research agenda to address unmet needs in the inflammatory bowel disease (IBD) research community and provide a roadmap for not only the Foundation but also the IBD research community at-large.
New York, New York – The American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and the Crohn’s & Colitis Foundation (Foundation), in partnership with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address vaccine utilizati
New York, New York – The Crohn’s & Colitis Foundation is launching a new open access journal to engage, inform, and catalyze dialogue on state-of-the-art, comprehensive care for the millions of Americans living with inflammatory bowel diseases (IBD).
CAMBRIDGE, England—PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation.
Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 1 in 100 Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.
The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.
Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.